Editas Medicine Inc
EDIT3.000USD
+0.280+10.29%
收盘 09/18, 16:00（美东）报价延迟15分钟
262.17M总市值
亏损市盈率 TTM
关于 Editas Medicine Inc 公司
Editas Medicine, Inc. 是一家临床阶段的基因组编辑公司。该公司专注于开发具有潜在变革性的基因组药物，以治疗多种严重疾病。该公司已开发出基于 CRISPR 技术的专有基因编辑平台。CRISPR 使用由酶组成的蛋白质-核糖核酸 (RNA) 复合物，包括 CRISPR 相关蛋白 9 (Cas9) 或 Cas12a（来自 Prevotella 和 Francisella 1 的 CRISPR，也称为 Cpf1），与旨在识别特定脱氧核糖核酸 (DNA) 序列的引导核糖核酸 (RNA) 分子结合。该公司致力于体内给药基因编辑药物的开发，其中将药物注射或输注到患者体内以编辑其体内的细胞。其主要项目 reni-cel 是一种实验性的体外基因编辑药物，用于治疗镰状细胞病 (SCD)，这是一种导致过早死亡的严重遗传性血液病，以及输血依赖性β地中海贫血 (TDT)。
公司简介
公司代码EDIT
公司名称Editas Medicine Inc
上市日期Feb 03, 2016
CEODr. Gilmore O'Neill
员工数量246
证券类型Ordinary Share
年结日Feb 03
公司地址11 Hurley St
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02141-2110
电话16174019000
网址https://www.editasmedicine.com/
公司代码EDIT
上市日期Feb 03, 2016
CEODr. Gilmore O'Neill
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
16.37K
-2.72%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
Independent Director
Independent Director
--
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
16.37K
-2.72%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月23日 周六
更新时间: 8月23日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
7.96%
BlackRock Institutional Trust Company, N.A.
6.87%
Geode Capital Management, L.L.C.
2.18%
Two Sigma Investments, LP
2.14%
Millennium Management LLC
2.09%
其他
78.76%
持股股东
持股股东
占比
The Vanguard Group, Inc.
7.96%
BlackRock Institutional Trust Company, N.A.
6.87%
Geode Capital Management, L.L.C.
2.18%
Two Sigma Investments, LP
2.14%
Millennium Management LLC
2.09%
其他
78.76%
股东类型
持股股东
占比
Investment Advisor
25.88%
Investment Advisor/Hedge Fund
11.36%
Hedge Fund
7.13%
Research Firm
4.57%
Individual Investor
0.30%
Bank and Trust
0.25%
Family Office
0.18%
Venture Capital
0.15%
Insurance Company
0.03%
其他
50.15%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
530
48.16M
57.53%
-24.49M
2025Q1
560
48.21M
57.60%
-23.68M
2024Q4
576
55.95M
67.78%
-11.28M
2024Q3
585
59.63M
72.30%
-8.64M
2024Q2
584
60.69M
73.86%
-19.13M
2024Q1
583
72.72M
88.97%
+367.05K
2023Q4
602
63.06M
77.30%
-13.98M
2023Q3
641
65.84M
80.91%
-11.78M
2023Q2
659
66.65M
82.05%
-208.12K
2023Q1
669
56.55M
82.00%
-9.39M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
7.47M
8.92%
+643.26K
+9.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.08M
7.26%
-551.77K
-8.32%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.94M
2.32%
+135.21K
+7.48%
Mar 31, 2025
Two Sigma Investments, LP
2.46M
2.94%
-841.30K
-25.45%
Mar 31, 2025
State Street Global Advisors (US)
1.85M
2.21%
-26.11K
-1.39%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.61M
1.92%
-551.03K
-25.52%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.55M
3.05%
+1.36M
+113.76%
Mar 31, 2025
UBS Asset Management Switzerland AG
1.17M
1.4%
+1.17M
--
Jan 31, 2025
SELECTRA Management Company S.A.
1.10M
1.32%
+600.00K
+118.81%
Apr 30, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
WisdomTree BioRevolution Fund
1.94%
Invesco NASDAQ Future Gen 200 ETF
0.67%
AXS Green Alpha ETF
0.38%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
查看更多
WisdomTree BioRevolution Fund
占比1.94%
Invesco NASDAQ Future Gen 200 ETF
占比0.67%
AXS Green Alpha ETF
占比0.38%
iShares Micro-Cap ETF
占比0.05%
Invesco Nasdaq Biotechnology ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
iShares Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
